Form 4: RA Capital Boosts Vor Biopharma Stake, Director Gets Options

RA Capital Management, a significant shareholder and director, increased its indirect beneficial ownership in Vor Biopharma Inc. by acquiring common stock and stock options.

Summary

• RA Capital Healthcare Fund, L.P. indirectly acquired 4,625,346 shares of Vor Biopharma Inc. common stock at a price of $10.81 per share on December 18, 2025.
• Following this transaction, RA Capital Healthcare Fund, L.P. beneficially owns 5,404,998 shares of common stock.
• Dr. Andrew Levin, a director of Vor Biopharma and a Partner at RA Capital Management, was granted 3,000 stock options with an exercise price of $12.80 on December 18, 2025.
• These options will vest in 36 equal monthly installments starting December 18, 2025, and expire on December 17, 2035.
• Dr. Levin holds these options for the benefit of RA Capital Healthcare Fund, L.P., with any proceeds offsetting advisory fees.
• RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah are reporting persons, all identified as Directors and 10% Owners of Vor Biopharma Inc.

Sentiment

Score: 7

Explanation: The filing indicates a significant increase in ownership by a major institutional investor and director, suggesting strong confidence in the company's future. The grant of options to a director further aligns interests. While a routine disclosure, the nature of the transactions is positive.

Positives

• A significant institutional investor (RA Capital) increased its stake in Vor Biopharma, indicating confidence in the company's future prospects.
• A director (Dr. Andrew Levin) received stock options, aligning his interests with shareholder value, even though held for the benefit of the fund.

Future Outlook

No explicit future outlook or guidance is provided in this Form 4, which primarily reports insider transactions.

Management Comments

• Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
• Dr. Levin holds the option for the benefit of the Fund. Dr. Levin is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser.

Industry Context

This filing indicates continued investment by a specialized healthcare fund in a biopharma company, which is a common pattern in the sector where institutional investors often take significant stakes and board positions to guide development and signal confidence.

Comparison to Industry Standards

• The acquisition of additional shares by a 10% owner and director is a strong signal of confidence, often seen as a positive indicator compared to general market sentiment in the biopharma industry.
• The grant of stock options to a non-employee director, even if held for the benefit of an investment fund, is a standard compensation practice to align interests, similar to practices at other biopharma companies.

Related Party Transactions

• The stock option granted to Dr. Andrew Levin, a director of Vor Biopharma and a Partner at RA Capital Management, for the benefit of RA Capital Healthcare Fund, L.P., represents a related party transaction due to the interconnected roles and financial interests.

Stakeholder Impact

• Shareholders: The increased stake by a major institutional investor could be seen as a positive signal, potentially boosting investor confidence.
• Management: The alignment of a director's interests (via options) with the company's performance is generally positive for management incentives.

Key Dates

Recommendation

The significant increase in beneficial ownership by RA Capital Management, a major institutional investor and director, signals strong confidence in Vor Biopharma. This insider buying, coupled with the grant of stock options to a director, suggests positive internal sentiment. However, a Form 4 primarily reports transactions and does not provide comprehensive financial or operational details to warrant a 'buy' or 'sell' recommendation without further fundamental analysis. Therefore, a 'hold' recommendation is appropriate, encouraging investors to maintain their position or conduct deeper due diligence.

Keywords

Vor Biopharma, VOR, RA Capital Management, Insider Trading, Form 4, Stock Acquisition, Stock Options, Beneficial Ownership, Biopharma, Healthcare Investment